Clinical trial
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Intravenous Tedisamil Sesquifumarate in the Rapid Conversion to Normal Sinus Rhythm in Male Subjects With Recent Onset Atrial Fibrillation or Flutter
NCT00126061 is registered in ClinicalTrials.gov with Solvay Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Intravenous Tedisamil Sesquifumarate in the Rapid Conversion to Normal Sinus Rhythm in Male Subjects With Recent Onset Atrial Fibrillation or Flutter
- Lead sponsor
- Solvay Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 31, 2004
- Completion date
- January 31, 2006
- Enrollment
- Not reported
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.